Pfizer Reaffirms 2026 Guidance After Strong Q1; Transition Story Unchanged

What happened

Pfizer reported strong first-quarter 2026 results and reaffirmed its full-year 2026 guidance, including revenue of $59.5-62.5B and adjusted EPS of $2.80-3.00. This aligns with the Deep Value Master Report's base case, which expects cost savings and stable non-COVID/non-LOE growth to protect margins. The reaffirmation is a positive check on a key thesis breaker—the report had flagged that failure to hold guidance would be a reason to reduce. However, the underlying headwinds from a ~$1.5B LOE impact and IRA pricing on Eliquis remain, and the strong Q1 may include one-time benefits. The market will watch whether this is proof of execution or a delay of inevitable pressure.

Implication

The reaffirmation supports the base case valuation of ~$29, but the stock at $26.8 already prices this. Upside to $33 requires visible oncology acceleration and stable Eliquis pricing. Investors should use a $24 entry for a better margin of safety, as the LOE wave and IRA headwinds still pose medium-term risk.

Thesis delta

The reaffirmation slightly increases the probability of the base case (from 50% to ~55%) as management did not raise LOE estimates nor flag COVID inventory charges, reducing bear-case risk. However, the bull case still needs proof of oncology acceleration (e.g., Padcev EU approval). The overall thesis remains unchanged: Pfizer is a transition story requiring 1-2 quarters of evidence to increase conviction.